問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Radiation Therapy

Division of Urology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

林哲弘Lin, Che-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) -8 years -4 個月

  • windsun@gmail.com

Recruiting Trial

156Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林哲弘

List

252Cases

2023-03-01 - 2024-03-29

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2021-10-21 - 2023-10-27

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2020-10-16 - 2024-04-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-08-01 - 2024-11-29

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-10-01 - 2021-03-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated1Sites

白禮源
China Medical University Hospital-Taipei

未分科

2026-01-15 - 2043-05-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-03-01 - 2030-07-16

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2017-08-01 - 2022-12-31

Phase III

Not yet recruiting
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Pracinostat

Participate Sites
9Sites

Terminated7Sites

2016-12-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double Blind, Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Venetoclax (ABT-199)

Participate Sites
5Sites

Terminated4Sites

蕭樑材
Taipei Veterans General Hospital

Division of Hematology & Oncology

2021-11-01 - 2022-08-29

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

1 17 18 19 20 21 26
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB